| Assessment Status | Rapid Review Complete |
| HTA ID | 24038 |
| Drug | Enfortumab vedotin in combination with pembrolizumab |
| Brand | Padcev®in combination with Keytruda® |
| Indication | Enfortumab vedotin in combination with pembrolizumab is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 23/09/2024 |
| Rapid review completed | 22/10/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
